Table 1.
Clinical trials of targeted therapies in cutaneous squamous cell carcinoma (CSCC) (revised until 29 January 2020).
| Drug | Treatment | Conditions | Current State | NCT Code |
|---|---|---|---|---|
| Cetuximab | Alone | Locally advanced and metastatic CSCC surgically unresectable |
Completed (28% response rate, 6% complete remission, 2% partial remission) |
NCT00240682 |
| Alone | Locally advanced and metastatic CSCC surgically unresectable |
Completed | NCT03325738 | |
| Alone (neoadjuvant therapy) | Aggressive locally advanced CSCC | Recruiting | NCT02324608 | |
| Combination with post-operative radiation |
Locally advanced head and neck CSCC | Active, not recruiting | NCT01979211 | |
| Combination with pembrolizumab | Recurrent/metastatic CSCC | Recruiting | NCT03082534 | |
| Combination with lenvatinib |
Advanced CSCC | Recruiting | NCT03524326 | |
| Combination with avelumab |
Advanced CSCC | Recruiting | NCT03944941 | |
| Gefitinib | Alone (neoadjuvant therapy) | Locally advanced/recurrent CSCC | Completed (45.5% response rate) | NCT00126555 |
| Alone | Metastatic or locorregional recurrent |
Completed (16% response rate) | NCT00054691 | |
| Erlotinib | Alone | Recurrent/metastatic CSCC | Completed (10% response rate) | NCT01198028 |
| Combination with radiotherapy |
Advanced head and neck CSCC |
Completed | NCT00369512 | |
| Alone (before surgery) | Head and neck CSCC | Active, not recruiting | NCT00954226 | |
| Cobimetinib | Combination with atezolizumab |
CSCC | Recruiting | NCT03108131 |